Algert Global LLC Has $1.32 Million Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Algert Global LLC lifted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 831.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 118,290 shares of the biotechnology company’s stock after buying an additional 105,593 shares during the period. Algert Global LLC owned about 0.05% of ADMA Biologics worth $1,322,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Mesirow Institutional Investment Management Inc. acquired a new position in ADMA Biologics during the first quarter worth $17,221,000. Bank of Montreal Can bought a new position in ADMA Biologics in the 2nd quarter valued at $17,886,000. D. E. Shaw & Co. Inc. boosted its stake in ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after purchasing an additional 1,442,799 shares in the last quarter. Castleark Management LLC acquired a new stake in shares of ADMA Biologics in the first quarter valued at $5,400,000. Finally, Hillsdale Investment Management Inc. raised its holdings in shares of ADMA Biologics by 41,893.3% in the first quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock valued at $4,157,000 after buying an additional 628,400 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Transactions at ADMA Biologics

In related news, Director Young Kwon sold 60,000 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the transaction, the director now owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. The disclosure for this sale can be found here. In the last three months, insiders sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ADMA shares. Mizuho upped their price target on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, HC Wainwright upped their price target on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $15.50.

ADMA Biologics Stock Up 0.4 %

Shares of NASDAQ:ADMA opened at $19.57 on Friday. The stock has a market cap of $4.54 billion, a price-to-earnings ratio of -978.50 and a beta of 0.61. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. ADMA Biologics, Inc. has a 12-month low of $3.06 and a 12-month high of $20.37. The business’s 50 day moving average is $16.88 and its 200 day moving average is $11.77.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. During the same period in the previous year, the company posted ($0.02) earnings per share. The business’s revenue was up 78.4% on a year-over-year basis. On average, sell-side analysts forecast that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.